Modification of exhaled air nitric oxide in patients with asthma – cortisone monotherapy or dual inhalation therapy?

Victoria Maria Ruta¹,A,D,F⁰, Nicoleta Stefania Motoc²,B,F⁰, Doina Adina Todea²,E⁰, Teodora Gabriela Alexescu³,D⁰, Dan Valean⁴,C⁰, Stefania Cozac⁴,C⁰, Sorina Cezara Coste⁴,D⁰, Razvan Andrei Coda³,B⁰, Rodica Ana Ungur⁶,D,E⁰, Carmen Monica Pop⁵,E,F⁰, Adina Man Milena²,D⁰

¹ 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania
² Department of Pneumology, 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania
³ Department of Internal Medicine, 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania
⁴ MD student, 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania
⁵ Faculty of Veterinary Medicine, University of Agricultural Science and Veterinary Medicine, Cluj-Napoca, Romania
⁶ Department of Rehabilitation, 'Iuliu Hatieganu' University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania

Abstract
Introduction. Asthma, a chronic lung disease, is a major health challenge worldwide with increased addressability to health services. There are different asthma phenotypes, which have different evolution and can be specifically tracked. The measurement of fractional expired nitric oxide (FeNO) with different devices reflects the eosinophilic inflammation of the airways, and can be used to evaluate the allergic phenotype and predict the treatment responses. The new GINA (Global Initiative for Asthma) guideline recommends FeNO monitoring to assess adherence to cortisone treatment in high doses before prescribing biological treatment, and as a means of monitoring the decrease in oral corticosteroid treatment.

Objective. The aim of the study is to analyze the applicability of FeNO in monitoring response to therapy.

Materials and method. An observational study was carried out on 129 subjects with a previously established diagnosis of asthma. The research was based on the determination of FeNO with NOBreathe. Those with intermediate FeNO received a low dose of inhaled corticosteroids in mono/dual therapy, those with increased FeNO received medium ICS mono/dual therapy. FeNO testing, its values and doses of ICS were below the the ATS / ERS guidelines.

Results. FeNO reduction is strictly dependent on the cortisone dose. Applying the dual therapy from the beginning does not bring additional benefits in comparison with cortisone in monotherapy, in terms of FeNO value.

Conclusion. Recommendations that include FeNO testing can help monitor response to treatment.

Key words
asthma, dual therapy, fractional expired nitric oxide (FeNO), inhalation monotherapy, wheezing
From a pathophysiological point of view, asthmatic patients have an increased expression of inducible nitric oxide synthase (iNOS) in the airway epithelial cells, and an increased level of nitric oxide (NO) in the expired air [10, 11]. FeNO is a measure of airway inflammation assessment and oxidative stress, as mentioned above [12]. Also, the level of FeNO is well correlated with the presence and level of inflammation and decreases with glucocorticoid treatment [13].

The new GINA (Global Initiative for Asthma) guideline recommends measuring FeNO as an assessment tool for treating patients with difficult asthma. FeNO monitoring is indicated to assess adherence to cortisone treatment in high doses before prescribing biological treatment. The guide also recommends measuring FeNO as a means of monitoring the decrease in oral corticosteroid treatment [14].

The current study analysed the applicability of FeNO assessment in monitoring the response to therapy, evaluating current symptom control and predicting asthma exacerbations.

MATERIALS AND METHOD

An analytical and observational study was carried out on 129 subjects, all over 18 years of age, with a previously established diagnosis of asthma, with different persistent respiratory symptoms for at least 7 days.

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its latter amendments or comparable ethical standards. The study was granted ethics’ approval by the Ethics Committee of the ‘Hospital of Rehabilitation Eurotrat’ Gherla, Cluj county, Romania, in January 2018. Informed consent was obtained from each individual participating in the study. The study was carried out on all subjects between February – July 2018.

Inclusion criteria:
1) a diagnosis of asthma of at least 1 year;
2) the presence of respiratory symptoms in the past 7 days;
3) skin allergic tests, for evaluation of the atopic field, within the past year;
4) a pulmonary x-ray in the past year (a high prevalence of tuberculosis infection in Romania is well-known);

Exclusion criteria:
1) association with COPD (Chronic Obstructive Pulmonary Disease), Overlap syndrome;
2) continuous exposure to respiratory allergens (bakers, hairdressers, industrial toxic environment, etc.).

Smoking was not a reason for exclusion.

Study protocol: After inclusion/exclusion criteria, all patients were assessed at the time of presentation, during visit 1 (V1), after 3 months, during visit 2 (V2) and after 6 months, and on their last evaluation, during visit 3 (V3). All visits were in the morning, at approximately the same time, following the ATS (American Thoracic Society) test criteria for NO in expired air and the ATS spirometry guide. FeNO was measured twice, and a third measurement was required if there was more than 10% difference between the first 2 measurements [15].

FeNO decreased at the end of exercise in both normal and asthmatic subjects [16]. Therefore, to avoid errors, the patients rested for 30 minutes before testing. FeNO testing was the first manoeuvre performed, using the NObreath® device (breath NO test system intended to measure FeNO in parts per billion (ppb) in exhaled breath) [17].

The subject breathed room air with a temperature between 22–25 °C. Interpretation of the values was carried out following the ATS ‘Interpretation of FeNO for Clinical Applications’:
- Intermediate NO: between 25ppb – 50ppb;
- High level NO: over 50 ppb [14].

These cut-offs have been described for adult non-smoking subjects. It is well acknowledged that smoking reduces FeNO in both healthy and asthmatic subjects [18], and the magnitude of the reduction seems to depend on the daily cigarette consumption [19]. The magnitude of smoking can be assessed by carbon monoxide concentration in exhaled air which represents a sure proof of recent smoking [20], thus being able to correlate it with the reality of the FeNO value. Tobacco use is detrimental to health and all health professionals have the duty to intervene and initiate tobacco cessation. Prevention programmes should focus on the medical education of both children and parents [21].

Exposure to chemical substances can induce an exaggerated immune response in susceptible individuals. Farmers, printers, painters, cleaners, and wood/plastic/electrical/health care workers are considered as being at high-risk exposure [22]. These categories of patients are at risk for occupational asthma, with intensely increased, persistent FeNo values due to exposure to allergens. FeNO test at 2–48 hours after exposure to allergens is at a maximum [23].

VISIT METHODOLOGY

V1 – first visit. The patient filled-in the ACQ (Asthma Control Questionnaire) to assess symptoms in the past 7 days. The ACQ has strong measurement properties and has been fully validated for use in both clinical practice and clinical trials, starting with 1998 -1999 by both ATS / ERS companies. NO in the exhaled air was tested.

The last measurement was spirometry, according to ATS / ERS criteria, performed with the Spirobank II Basic spirometer.

Because asthma is a highly variable disease, symptoms might fluctuate substantially from day-to-day [24], and for that reason, the pretesting ACQ questionnaire was used to not evaluate FeNO in a patient with asthma exacerbation.

V2 – the second visit, after 3 months. The patient’s FeNO was tested.

V3 – the third visit, after 6 months. The patient’s FeNO was tested.

Depending on the FeNO value, intermediate and high level, the subjects were divided into 2 randomized groups of cortisone inhaler (ICS) therapy: ICS in monotherapy or dual therapy (ICS and Long-Acting Beta Agonist (LABA) combination). At the base of the randomization stood the dose of cortisone, small or medium category, according to GINA ICS low, medium and high doses [25].
1) Subjects with intermediate FeNO, 25ppb-50ppb, had an indication of inhalation treatment with low dose ICS (mono/dual dose).
2) Subjects with high FeNO, over 50 ppb, had an indication of inhalation treatment with a medium dose of ICS (mono/dual dose).
3) There was no randomization on high doses of cortisone.

Statistical analysis. Database processing was performed in Excel and interpretation by IBM SPSS v20.0. The tests used were the T-test for independent samples and the Chi-Squared test. Differences were considered significant when p < 0.05.

RESULTS

Patients presenting with worsening of the general condition during V2 were excluded from the study for further investigation. In 2 patients, the general condition worsens until the next visit, requiring further evaluation and the combination of new drugs for the undiagnosed comorbidities during V1, while one patient voluntarily withdrew.

Demographic data of subjects. The age distributions, body weights and heights did not differ significantly between the 2 groups. There was a significant correlation between the presence of atopic terrain and the NO value in the exhaled air [1] (Tab. 1; Fig. 1).

Elevated FeNO levels as a risk factor for persistent wheezing. FeNO measurement may serve as an additional parameter for predicting persistent wheezing in preschool children [26]. No association was found between other specific symptoms and FeNO values.

Changes in FENO levels after treatment

Modification of FeNO after therapy start. To compare the differences in NO values in the sample, the ANOVA test was used for means comparison. The average value of the initial NO was 45.41 ppb (+ – 33.00 standard deviation), while the average value of the NO after 3 months was 21.90 ppb (+ – 24.51 st. dev.) and 14.54 ppb (+- 12.42 st. dev.), respectively, after 6 months. Following the test, this difference is statistically significant (p= 0.0001) with a significant reduction of FeNO values in both groups of patients (Fig. 3).

Modification of FeNO depending on the cortisone dose – small/medium. Regarding the therapeutic arms and the FeNO modification under different doses and inhalation medications, FeNO modification was initially evaluated according to the cortisone dose (Fig. 4).

To highlight the existence of a link between the value of FeNO after 3 months of treatment and the dose of cortisone, the T-test for independent sample was used. The difference after 3 months for patients treated with a low dose of cortisone
was 19.07 ppb (+ – 13.39 st. dev.), whereas in patients treated with a medium dose of cortisone it was 52.07 ppb (+ 35.19 st. dev.).

Using the T-test for independent samples, it was concluded that this difference was statistically significant (p=0.005), the average dose of cortisone being significantly higher than the small dose, with a much faster reduction of FeNO values.

**Modification of FeNO according to the randomization arm.** In monotherapy, there was an average decrease of 33.34 ppb, while in dual therapy there was an average decrease of 28.19 ppb. This difference was not statistically significant (Fig. 5).

**DISCUSSION**

High FeNO is evidence of uncontrolled inflammation and is associated with increased risk for asthma exacerbations and potential future deterioration, even when there is a lack of corroborating symptoms or normal lung function [27].

Numerous studies on other pathologies proved that inflammation markers were significantly correlated with muscle strength, walking distance and cognitive impairment [28]. Therefore, in the present study, the FeNO measurement was performed after excluding the previously listed factors, and after a 30-minute seated rest period.

The use of ICS is proven to be effective in treating asthma [29]. ICS can reduce asthma symptoms and inhibit the activity of inflammatory cells, including eosinophils, T lymphocytes, mast cells, macrophages, dendritic cells and neutrophils [30]. These remarkable effects of corticosteroids are produced by suppressing the production of chemotactic mediators, adhesion molecules and inhibiting the survival of these inflammatory cells in the airways [31].

Starting from specialized literature data, the aim of the current study was to follow the modification of NO in asthmatic subjects according to the administration of ICS in monotherapy, compared to dual therapy and depending on the used doses of cortisone.

Both groups on ICS mono/dual therapy showed FeNO enhancement, after 3 and 6 months. In conclusion, the FeNO value is not influenced by mono / dual therapy.

In conclusion, the administration of ICS is mandatory. Twenty-two studies demonstrated that FeNO levels declined after the administration of ICS. The response was seen after 4 – 8 weeks of treatment, although one study showed reduction after 10 days, without further reduction observed at 40 days [32]. In the current study, there was a significant reduction of FeNO after 3 months, regardless of the therapeutic arm. During the 3-month evaluation, a lower FeNO was observed in patients with an average dose of cortisone, compared with patients with a low dose, regardless of monotherapy or dual therapy; therefore, the decline in FeNO is ICS dose-dependent.

In patients with uncontrolled asthma treated with ICS, the guidelines recommend increasing the dose of ICS or adding a LABA to the low doses of ICS [33]. There are studies which suggest that adding a LABA to ICS may be more beneficial in controlling asthma than increasing the dose of corticosteroids alone [34].

Regarding the primary intention administration, dual or monotherapy, this study did not find superior efficacy of dual therapy in reducing FeNO, with monitoring after 3 and 6 months. In this context, and the current guidelines for asthma, the ICS/LABA treatment is recommended when asthma is not well controlled by low maintenance ICS plus Short-Acting Beta Agonist (SABA) treatment. These recommendations are not based on efficacy, but the higher cost of combination drugs [35, 36]. However, the combination of ICS in low doses with rapid onset LABA is effective for reducing symptomatology and increasing the quality of life.

FeNO levels decrease rapidly after initiation of ICS therapy, whether dual monotherapy, as shown in the presented study, while literature confirms that FeNO level increases very rapidly after discontinuation of corticosteroid therapy [37]. The dynamic follow-up of FeNO level helps to assess whether the asthma is under control, and guide ICS treatment in asthmatic patients.

The ATS clinical guidelines suggest that FeNO over 50 ppb indicate the need for stepping-up treatment, but no clear recommendations exist for lower FeNO levels [38].

There are studies which claim that FeNO is the most sensitive inflammatory marker for evaluating the anti-inflammatory effects of ICS on asthmatic patients. However, the reduction of FeNO after ICS treatment may not ensure optimal suppression of airway inflammation [39], and may not be able to require increasing / decreasing of ICS doses solely on its value [40]. Further studies are required for a more definitive evaluation.

**CONCLUSIONS**

Although it was not within the scope of this study, the association was observed between wheezing and increased FeNO in patients with atopic terrain, which is consistent with data underlined by literature, numerous publications highlighting much higher FeNO values and the presence of atopic terrain, proven by positive skin tests or bronchial challenge tests [32].

Unfortunately, the evaluation of FeNO is not a sensitive or specific marker. It can be indicated for the evaluation of asthma, but does not enter the standard protocol.

**Study limitations.** Limitation of the study were the small number of subjects included, and that the patients could not be monitored for a longer period to evaluate FeNO at the therapy step-down, because they were not locals and access to rural areas was difficult. There was no control group and absolute FeNO values varied depending on the device used.
Acknowledgments

The first two authors have equal rights to this paper.

REFERENCES

1. Global Strategy for Asthma Management and Prevention (2018 update) https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdf (access:2020.09.08)
2. Masefield S, Edwards J, Hansen K, Hamerlijnck D, Lisspers K, Schee M van der, et al. The future of asthma research and development: a roadmap from the European Asthma Research and Innovation Partnership (EARIP). Eur Respir J 2017; 49(5).
3. Croitoru A, Bogdan MA. [Evidences related to pulmonary rehabilitation in the respiratory pathology]. Pneumol Bucur Rom. 2014 Jun; 63(2): 88–90, 92–5.
4. Nistor AR, Onac I, Stefanescu A, Borda IM, Ciortea V, Ungur R. EBSCHost | 1088000145 | The role of singing therapy in pulmonary rehabilitation. Palestra of the Third Millennium Civilization & Sport. 2015; 16(2).
5. Georas SN, van Wijngaarden E, Rich DQ. Air pollution and asthma incidence: doubt no more? Lancet Respir Med 2015 Dec; 3(12): 902–3.
6. Rezaei Vandahlí N, Koolvand A, Ranbarj A, et al. Oxidative toxic stress and p53 level in healthy subjects occupationally exposed to outdoor air pollution – a cross-sectional study in Iran. Ann Agric Environ Med. 2020. doi: 10.26444/aam/126313
7. Ungur R, Dronca M, Crăciun EC, Rusu RL, Văleanu M, Onac I, et al. Improvement of total antioxidant status, a possible bioeffect of the ultrasound therapy – a pilot study. Rev Romana Med Lab. 2011; 19(2): 177–83.
8. Pignatelli P, Menichelli D, Pastori D, Violi F. Oxidative stress and cardiovascular disease: new insights. Kardiol Pol. 2018; 76(4): 713–22.
9. Cozma A, Sitar-Taut A, Orășan O, Leucuta D, Alexescu T, Stan A, et al. Determining Factors of Arterial Stiffness in Subjects with Metabolic Syndrome. Metab Syndr Relat Disord. 2018 Sep 5; 16(9): 490–6.
10. Barnes PJ, Liew F.Y. Nitric oxide and asthmatic inflammation. Immunol Today. 1995 Mar 15; 16(3): 128–30.
11. Lemière C, Ernst P, Olivenstein R, Yamauchi Y, Govindaraju K, Ludwig MS, et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: Eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol. 2006 Nov 1; 118(3): 1033–9.
12. Matacuta I, Neamtu MB, Bodrug N, Dobrota L, Neamtu ML, Caprita H. Metode de explorare funcțională pulmonară. Rev Stiintifico-Practico Inf Med. 2013; 1(21): 32–6.
13. Hoyte FCL, Gross JM, Katali RK. Exhaled Nitric Oxide: An Update. Immunol Allergy Clin North Am. 2018; 38(4): 573–85.
14. Pocket guide for asthma management and prevention (GINA-2019) https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf (access:2020.09.08)
15. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg MS, et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: Eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol. 2006 Nov 1; 118(3): 1033–9.
16. Malinovschi A, Van Muylen M, Michiels S, Michiels A. FeNO as a predictor of asthma control improvement after starting inhaled steroid treatment. Nitric Oxide. 2014; 40: 110–6.
17. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic Inflammation in Severe Persistent Asthma. Am J Respir Crit Care Med. 2011 Sep 1; 184(5): 602–15.
18. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31(1): 143–78.
19. Hauber H-P, Gottfried M, Newman K, Danda R, Servi RJ, Christodouloupoulos P, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol. 2003 Jul; 112(1): 58–63.
20. Hossny E, Rosario N, Lee BW, Singh M, El-Ghoneimy D, SOH JY, et al. The use of inhaled corticosteroids in pediatric asthma: update. World Allergy Organ J https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982274/ (access: 2020.09.08)
21. Wang Z, Pioanni P, Keogh K, Zaiem F, Alsawas M, Alahdab F, et al. The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Agency for Healthcare Research and Quality; https://effectivehealthcare.ahrq.gov/topics/asthma-nitric-oxide/research/(access: 2020.09.08)
22. Zetterström O, Buhl R, Mellem H, Perpítà M, Hedman J, O’Neill S, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J. 2001 Aug 1; 18(2): 262–8.
23. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. The Lancet. 1994 Jul 23; 344(8917): 219–24.
24. Fingleton J, Hardy J, Baggott C, Pilcher J, Corin A, Hancox RI, et al. Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma. BMJ Open Respir Res https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647477/ (access:2020.09.08)
25. Budin CE, Maierean AD, Iancos ES, Socaci A, Buzoianu AD, Alexescu TG, et al. Nocturnal Hypopnoea, a Key Parameter in Overlap Syndrome. Rev Chim. 2019 Mar 15; 70(2): 449–54.
26. Liu L, Urban P, Hunt JF, Wilkinson P, Lanning K, Gastos B. Changes in Exhaled Nitric Oxide and Breath pH during Fluticasone Wean in Asthma. Respiration. 2010; 79(3): 193–9.
27. Malinovschi A, Van Muylen M, Michiels S, Michiels A. FeNO as a predictor of asthma control improvement after starting inhaled steroid treatment. Nitric Oxide. 2014; 40: 110–6.
28. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic Inflammation in Severe Persistent Asthma. Am J Respir Crit Care Med. 1999 Nov 1; 160(5): 1532–9.
29. Sl J, P H, Jo C, Em F, Rj H, Cr M, et al. Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship. Nitric Oxide. 2014; 40: 110–6.
30. Battani Z, Pioanni P, Keogh K, Zaiem F, Alsawas M, Alahdab F, et al. The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Agency for Healthcare Research and Quality; https://effectivehealthcare.ahrq.gov/topics/asthma-nitric-oxide/research/(access: 2020.09.08)
31. Malinovschi A, Van Muylen M, Michiels S, Michiels A. FeNO as a predictor of asthma control improvement after starting inhaled steroid treatment. Nitric Oxide. 2014; 40: 110–6.
32. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic Inflammation in Severe Persistent Asthma. Am J Respir Crit Care Med. 1999 Nov 1; 160(5): 1532–9.
33. Sj J, P H, Jo C, Em F, HI, Cr M, et al. Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship. Eur Respir J. 2002 Sep 1; 20(3): 601–8.